Filing Details
- Accession Number:
- 0001593968-20-002209
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-18 14:15:48
- Reporting Period:
- 2020-11-16
- Accepted Time:
- 2020-11-18 14:15:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1673772 | Rapt Therapeutics Inc. | RAPT | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1635616 | G. Dirk Brockstedt | C/O Rapt Therapeutics, Inc., 561 Eccles Avenue South San Francisco CA 94080 | Chief Scientific Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-11-16 | 3,369 | $6.18 | 13,625 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-11-16 | 6,508 | $6.30 | 20,133 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-11-16 | 9,877 | $17.01 | 10,256 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2020-11-16 | 3,369 | $0.00 | 3,369 | $6.18 |
| Common Stock | Stock Option (right to buy) | Disposition | 2020-11-16 | 6,508 | $0.00 | 6,508 | $6.30 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 5,035 | 2028-03-27 | No | 4 | M | Direct | |
| 14,151 | 2029-03-27 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.
Billionaire Hedge Funds
